Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS
Key facts
- Where
- Chaïdári, GreeceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Source: NCT06889454, who can take part
Where in Greece
- Attikon University General HospitalChaïdári, GreeceContact: Vaia Lambadiari, ProfessorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Attikon Hospital
- Trial code
- NCT06889454
- Record updated
- 19 November 2025
- Original description
The aim of the present study is to investigate a) the presence of subclinical markers of vascular, myocardial and endothelial function in women with PCOS b) the acute alterations in these markers during the oral glucose tolerance test (OGTT) c) the impact of potential treatment interventions in these markers.Read full original descriptionShow less
The Effect of Different Treatment Options on Markers of Vascular, Myocardial and Endothelial Function in Women With Polycystic Ovary Syndrome and the Association With Metabolic and Hormonal Abnormalities of the Syndrome
The aim of the present study is to investigate a) the presence of subclinical markers of vascular, myocardial and endothelial function in women with PCOS b) the acute alterations in these markers during the oral glucose tolerance test (OGTT) c) the impact of potential treatment interventions in these markers.
Inclusion: Age > 16 years old; Diagonis of PCOS according to Rotterdam criteria: presence of two of the three of the following:; Clinical or biochemical hyperandrogenism; Anovulation or oligo-ovulation; Polycystic ovarian morphology (PCOM); Absence of treatment for PCOS the last six months; Patients who have the ability to understand and sign the consent form.
Exclusion: Treatment with contraceptive or metformin; Type 2 diabetes mellitus; Treatment for diabetes; Malignancy; Disorders with clinical presentation similar to PCOS: thyroid disease, hyperprolactinemia, and non-classic congenital adrenal hyperplasia (primarily 21-hydroxylase deficiency by serum 17-hydroxyprogesterone [17-OHP]), Cushing syndrome, acromegaly; Pregnancy; Lactation.